Neurodegenerative Diseases Market to reach USD 53 Billion by 2030 and grow steadily at a CAGR of 3.2%: Straits Research
27 mai 2022 11h30 HE
|
Straits Research
New York, United States, May 27, 2022 (GLOBE NEWSWIRE) -- Neurodegenerative diseases are a large and diverse group of disorders characterized by progressive deterioration of the function and...
InvestmentPitch Media Video Discusses FSD Pharma, a Life Sciences Holding Company, and the Closing of its Sale of Non-Core Assets for $16.4 million
11 mai 2022 06h00 HE
|
InvestmentPitch Media and FSD Pharma
VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a life sciences holding company dedicated to building a portfolio of assets and...
Media Advisory: KingSett CEO Jon Love and Special Guests Rappel from Roof of 700 University Ave to Open MS Million Dollar Tower Challenge
05 mai 2022 14h22 HE
|
Multiple Sclerosis Society of Canada
Monday, May 9, 2022 – 8:30am ET 700 University Avenue (SW corner of University and College St.), Toronto, ON Live broadcast and photo opportunity from base of rappel; option for media to rappel...
With 6.3% CAGR, Multiple Sclerosis Drugs Market Size Worth USD 41.99 Billion in 2028
26 avr. 2022 05h50 HE
|
Fortune Business Insights
Pune, India, April 26, 2022 (GLOBE NEWSWIRE) -- The global multiple sclerosis drugs market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to...
Healios AG Announces Addition of Anna Walz to Board of Directors
12 avr. 2022 14h00 HE
|
Healios AG
BASEL, Switzerland, April 12, 2022 (GLOBE NEWSWIRE) -- Healios AG, a MedTech company focused on developing and validating digital biomarkers since 2014, announced that Anna Walz has been appointed...
The MS Read-a-Thon Adventures Continues Through March with a $110,000 Goal
10 mars 2022 11h51 HE
|
Multiple Sclerosis Society of Canada
Toronto, O.N., March 10, 2022 (GLOBE NEWSWIRE) -- The Multiple Sclerosis (MS) Society of Canada has extended its virtual MS Read-a-Thon event until March 20, 2022, providing children and families...
Global Systemic Scleroderma Treatment Market to Surpass US$ 2,027.4 Million by 2028, Says Coherent Market Insights (CMI)
10 mars 2022 08h30 HE
|
CMI
SEATTLE, March 10, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global systemic scleroderma treatment market is estimated to be valued at US$ 1,520.1 million in 2021 and is...
AB Science annonce la publication de l’étude clinique pivot de Phase 3 du masitinib dans les formes progressives de la sclérose en plaques dans la revue Neurology® Neuroimmunology & Neuroinflammation
22 févr. 2022 12h08 HE
|
AB Science
COMMUNIQUE DE PRESSE PUBLICATION DE L’ETUDE CLINIQUE PIVOT DE PHASE 3 DU MASITINIB DANS LES FORMES PROGRESSIVES DE LA SCLÉROSE EN PLAQUES DANS LA REVUE NEUROLOGY®: NEUROIMMUNOLOGY &...
AB Science announces the publication of the masitinib positive pivotal Phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & Neuroinflammation
22 févr. 2022 12h08 HE
|
AB Science
PRESS RELEASE PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS IN THE JOURNAL NEUROLOGY®: NEUROIMMUNOLOGY & NEUROINFLAMMATION Paris, 22...
AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency
02 févr. 2022 12h13 HE
|
AB Science
PRESS RELEASE AB SCIENCE HAS BEEN AUTHORIZED BY THE SWEDISH MEDICAL PRODUCTS AGENCY TO INITIATE CONFIRMATORY PHASE III TRIAL OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS SWEDEN IS THE...